Ensure your discussion guide’s English is not plain, but clear
One of the easiest traps in international primary research is assuming that “plain English” is automatically clear English. When preparing a primary […]
Category: Strategy Consulting
Using analogs to support your strategy
Whenever analogs come up in pharma strategy, someone usually says: “But that situation wasn’t the same as ours.” In recent weeks, I’ve […]
Wearables in Clinical Trials – Form Factor
Over recent months, I’ve been exploring novel diagnostic tools, with a particular focus on digital cognitive assessments. Along the way, I came […]
Why Your Advisory Board Shouldn’t Be Moderated by the Team Most Invested in the Answer
You’ve spent months working on the asset. The clinical strategy has been debated. The data have been reviewed from every angle. The […]
Project History X: The Project That Outlived Its Parents
Every Project Plan Assumes People Don’t Leave. Reality Check: They Do. A few years ago, I took over a project that was […]
Project History VII-IX: Why the Best Go/No-Go Research Starts by Trying to Kill the Project
Intro Teams often fail not because of a lack of data, but because of research that confirms what they already believe. The […]
Project History VI: Asset Landscaping for Pharma BD and why your biotech website might be hindering your chances of being “spotted”
When you read the Pharma news sites and analysis on LinkedIn about drug patent cliffs, you might think pharmaceutical companies are sitting […]
Project History V: Your Competitor Doesn’t Always Look Like You; Why companies miss competitive threats hiding in plain sight.
Introduction: Spotting the Threat You Didn’t Expect This week’s article is based on a project I completed earlier this year as part […]
Simon joins panel discussion Behind the Headlines
Early this week, I joined Chris Spivey on PharmaTech.com’s Behind the Headlines to discuss several of the previous week’s significant life science […]
‘First mover’ isn’t always an advantage for new drugs
~1.5 years ago I was reading a Financial Times article (FT.com) on obesity drugs and their order to market when my critical […]